1. Home
  2. TOVX vs CURX Comparison

TOVX vs CURX Comparison

Compare TOVX & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TOVX

Theriva Biologics Inc.

HOLD

Current Price

$0.17

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

CURX

Curanex Pharmaceuticals Inc

N/A

Current Price

$0.39

Market Cap

11.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TOVX
CURX
Founded
2001
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
11.6M
IPO Year
2012
2025

Fundamental Metrics

Financial Performance
Metric
TOVX
CURX
Price
$0.17
$0.39
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.8M
5.6M
Earning Date
06-19-2026
09-09-2025
Dividend Yield
N/A
N/A
EPS Growth
89.07
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.26
52 Week High
$1.50
$9.18

Technical Indicators

Market Signals
Indicator
TOVX
CURX
Relative Strength Index (RSI) 41.68 51.48
Support Level $0.17 $0.39
Resistance Level $0.26 $0.42
Average True Range (ATR) 0.01 0.07
MACD -0.00 -0.00
Stochastic Oscillator 3.91 24.80

Price Performance

Historical Comparison
TOVX
CURX

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

About CURX Curanex Pharmaceuticals Inc

Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.

Share on Social Networks: